Tan Kevin's most recent trade in Adeia Inc was a trade of 112,961 Common Stock done . Disclosure was reported to the exchange on March 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 112,961 | 392,908 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 76,820 | 412,255 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.69 per share. | 01 Mar 2026 | 57,473 | 335,435 (0%) | 0% | 20.7 | 1,189,116 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.69 per share. | 01 Mar 2026 | 32,614 | 279,947 (0%) | 0% | 20.7 | 674,784 | Common Stock |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 13.90 per share. | 27 Feb 2026 | 300,000 | 11,629,500 (13%) | 0% | 13.9 | 4,170,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 14.12 per share. | 27 Feb 2026 | 214,839 | 11,844,339 (13%) | 0% | 14.1 | 3,033,527 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 14.22 per share. | 27 Feb 2026 | 184,208 | 12,229,500 (14%) | 0% | 14.2 | 2,619,438 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 14.21 per share. | 27 Feb 2026 | 115,792 | 12,045,292 (14%) | 0% | 14.2 | 1,645,404 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 14.33 per share. | 27 Feb 2026 | 83,561 | 11,929,500 (13%) | 0% | 14.3 | 1,197,429 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 14.38 per share. | 27 Feb 2026 | 1,600 | 11,845,939 (13%) | 0% | 14.4 | 23,008 | Common Shares |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 10,625 | 21,250 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 10,625 | 104,826 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 5.82 per share. | 13 Feb 2026 | 5,404 | 99,422 (0%) | 0% | 5.8 | 31,469 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 04 Feb 2026 | 14,783 | 94,201 (0%) | 0% | 6.4 | 95,231 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 187,000 | 187,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 93,500 | 93,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 56,646 | 102,746 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 56,646 | 0 | - | - | Performance Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 33,075 | 99,225 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 33,075 | 135,821 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 29 Jan 2026 | 26,837 | 108,984 (0%) | 0% | 6.4 | 172,747 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 11,250 | 51,804 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 5.27 per share. | 09 Jan 2026 | 5,704 | 46,100 (0%) | 0% | 5.3 | 30,060 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.56 per share. | 19 Oct 2025 | 8,117 | 310,561 (0%) | 0% | 16.6 | 134,418 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 62,500 | 62,500 | - | - | Restricted Stock Units | |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 10.12 per share. | 01 Aug 2025 | 1,000,000 | 11,029,500 (12%) | 1% | 10.1 | 10,120,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 11.68 per share. | 01 Aug 2025 | 200,000 | 11,329,500 (13%) | 0% | 11.7 | 2,336,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 11.34 per share. | 01 Aug 2025 | 100,000 | 11,129,500 (13%) | 0% | 11.3 | 1,134,000 | Common Shares |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 79,130 | 318,678 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.72 per share. | 01 Mar 2025 | 25,583 | 239,548 (0%) | 0% | 15.7 | 402,165 | Common Stock |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.92 per share. | 28 Feb 2025 | 500,000 | 9,929,500 (11%) | 0% | 7.9 | 3,960,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.85 per share. | 28 Feb 2025 | 399,280 | 8,828,780 (10%) | 0% | 7.9 | 3,134,348 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.02 per share. | 28 Feb 2025 | 351,962 | 9,281,462 (10%) | 0% | 8.0 | 2,822,735 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 28 Feb 2025 | 148,038 | 9,429,500 (11%) | 0% | 8 | 1,184,304 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.97 per share. | 28 Feb 2025 | 100,720 | 8,929,500 (10%) | 0% | 8.0 | 802,738 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.09 per share. | 28 Feb 2025 | 100,000 | 10,029,500 (11%) | 0% | 8.1 | 809,000 | Common Shares |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,625 | 35,414 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,625 | 31,875 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 13 Feb 2025 | 3,164 | 32,250 (0%) | 0% | 4.0 | 12,529 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 132,300 | 132,300 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2025 | 11,250 | 28,862 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2025 | 11,250 | 22,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.89 per share. | 09 Jan 2025 | 4,073 | 24,789 (0%) | 0% | 3.9 | 15,849 | Common Stock |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.09 per share. | 05 Dec 2024 | 500,000 | 8,429,500 (9%) | 0% | 9.1 | 4,545,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.01 per share. | 05 Dec 2024 | 400,000 | 7,929,500 (9%) | 0% | 9.0 | 3,604,000 | Common Shares |
| Aurinia Pharma Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.91 per share. | 05 Dec 2024 | 300,000 | 7,529,500 (8%) | 0% | 8.9 | 2,673,000 | Common Shares |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.44 per share. | 19 Oct 2024 | 8,101 | 264,890 (0%) | 0% | 12.4 | 100,776 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.60 per share. | 01 Sep 2024 | 4,366 | 272,991 (0%) | 0% | 12.6 | 55,012 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 80,720 | 277,106 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.53 per share. | 01 Mar 2024 | 15,606 | 196,386 (0%) | 0% | 11.5 | 179,937 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 42,500 | 42,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Tan Kevin | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 11,250 | 13,243 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 09 Jan 2024 | 3,935 | 9,308 (0%) | 0% | 8.2 | 32,267 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.54 per share. | 20 Jul 2023 | 10,885 | 222,641 (0%) | 0% | 11.5 | 125,613 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.01 per share. | 01 Jul 2023 | 793 | 233,526 (0%) | 0% | 11.0 | 8,731 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 8.34 per share. | 31 May 2023 | 699 | 234,319 | - | 8.3 | 5,830 | Kevin Tanji |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 69,644 | 240,374 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.85 per share. | 01 Mar 2023 | 6,754 | 233,620 (0%) | 0% | 9.9 | 66,527 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 32,220 | 170,730 (0%) | 0% | 0 | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 90,000 | 90,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2022 | 63,937 | 137,946 (0%) | 0% | 0 | Common Stock | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 340,000 | 340,000 | - | - | Employee Stock Option (right to buy) | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 72,000 | 77,000 (0%) | 0% | 0 | Common Stock | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.03 per share. | 02 Dec 2021 | 5,000 | 5,000 (0%) | 0% | 3.0 | 15,127 | Common Stock |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2021 | 750,000 | 750,000 | - | - | Employee Stock Option (right to buy) |